Announcements

Announcements

Paul G. Allen Frontiers Group [to 29 Jun 2019]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
No new digest content identified.

BMGF – Gates Foundation [to 29 Jun 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 29 Jun 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 29 Jun 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 29 Jun 2019]
http://cepi.net/
No new digest content identified.

Clinton Health Access Initiative, Inc. (CHAI) [to 29 Jun 2019]
https://clintonhealthaccess.org/about/
No new digest content identified.

EDCTP [to 29 Jun 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 29 Jun 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

European Medicines Agency [to 29 Jun 2019]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.

European Vaccine Initiative [to 29 Jun 2019]
http://www.euvaccine.eu/news-events
No new digest content identified.

FDA [to 29 Jun 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.

Fondation Merieux [to 29 Jun 2019]
http://www.fondation-merieux.org/
No new digest content identified.

Gavi [to 29 Jun 2019]
https://www.gavi.org/
27 June 2019
New 2021-2025 high level strategy to leave no-one behind with immunisation approved by Gavi Board
[See Milestones above for detail]

GHIT Fund [to 29 Jun 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 29 Jun 2019]
https://www.theglobalfund.org/en/news/
News
Global Fund Praises UK for Increasing Pledge by 16 Percent
29 June 2019
The Global Fund congratulated the United Kingdom for demonstrating outstanding leadership in global health with a strong commitment to help end AIDS, tuberculosis and malaria and save millions of lives around the world

News
Global Fund Welcomes Japan’s Commitment to Save One Million Lives
24 June 2019

Hilleman Laboratories [to 29 Jun 2019]
http://www.hillemanlabs.org/
26 June 2019
Hilleman Laboratories licenses Oral Cholera Vaccine Hillchol® to Bharat Biotech
Collaboration seeks to accelerate the development, licensure, manufacture and supply of an affordable, next-generation Cholera vaccine to support access in low and middle-income coun-tries
New Delhi, 26th June 2019: Hilleman Laboratories, a global research and development organization focused on delivering high-impact and affordable vaccines, announced today that it has entered into a collaboration with Bharat Biotech International Ltd. (BBIL), a leading vaccine and biotechnology company in India for further development, manufacturing and commercialization of its next-generation Oral Cholera Vaccine, Hillchol®. This collaboration will strengthen the ability of both organizations towards prevention of Cholera through rapid and cost-effective deployment of vaccine doses in low and middle-income countries…
…Hillchol® was designed at the University of Gothenburg in Sweden and subsequently developed by Hilleman Labs including demonstration of safety and immunogenicity in an age de-escalating Phase I/II clinical trial conducted in Bangladesh with the assistance of icddr,b and Incepta Vac-cines Ltd. For further development of Hillchol®, Hilleman Labs has entered into a licensing and manufacturing agreement with BBIL, who will scale the manufacturing process to commercial stage and establish product specifications required for WHO pre-qualification…

Human Vaccines Project [to 29 Jun 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

IAVI [to 29 Jun 2019]
https://www.iavi.org/newsroom
No new digest content identified.

 

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

IFRC [to 29 Jun 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.

IVAC [to 29 Jun 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
June 2019
IVAC-led PERCH study reveals viruses as new leading cause of global childhood pneumonia
Results from PERCH highlight the need for new vaccines, especially against respiratory syncytial virus

IVI [to 29 Jun 2019]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

JEE Alliance [to 29 Jun 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 29 Jun 2019]
http://www.msf.org/
Selected News; Project Updates, Reports
Democratic Republic of Congo
Urgent humanitarian response needed on unprecedented crises in…
Press Release 27 Jun 2019
:: People in the northeastern DRC province of Ituri are currently facing an unprecedented four concurrent crises.
:: The needs among people are great, with high levels of disease, yet MSF’s previous calls for help have gone unheeded.
:: MSF calls for other humanitarian organisations to urgently commit to the long-term scale up of assistance to people in Ituri.

El Salvador
La Peralta: a community organised by health
Project Update 27 Jun 2019

Mexico
Life amidst the violence: the strong women of Guerrero
Voices from the Field 27 Jun 2019

Access to medicines
Gilead fails to keep promise on access to lifesaving drug for peop… liposomal amphotericin B (L-AmB)
Press Release 27 Jun 2019

Yemen
The indirect consequences of war for people in Yemen
Project Update 25 Jun 2019

NIH [to 29 Jun 2019]
http://www.nih.gov/news-events/news-releases
June 25, 2019
NIH launches large TB prevention trial for people exposed to multidrug-resistant TB
— Study will compare delamanid to isoniazid for preventing TB disease in at-risk contacts.
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB. Study participants are at high risk for MDR-TB because they either have latent TB infection, immune systems suppressed by HIV or other factors, or are younger than age 5 years and therefore have a weak immune system…

PATH [to 29 Jun 2019]
https://www.path.org/media-center/
No new digest content identified.

Sabin Vaccine Institute [to 29 Jun 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.

UNAIDS [to 29 Jun 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
28 June 2019
No end to AIDS without respecting human rights

Positive movement: safety, trust and services for people who inject drugs

New modelling research shows partial progress in South Africa’s response to HIV

27 June 2019
Deported, denied access, discriminated against because of their HIV status

South Africa: pace really matters

26 June 2019
Civil society engagement in universal health coverage

25 June 2019
Pushing for harm reduction success in Burundi

UNICEF [to 29 Jun 2019]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
UN Headquarters to host groundbreaking discussion on vaccine misinformation and growing distrust
Experts, UN officials and private sector representatives to convene to address drivers of vaccine hesitancy and stagnating immunization rates worldwide
27 June 2019

Press release
Migrant children in the U.S. lack protection and services needed to ensure their wellbeing
As two-year-old Valeria’s death shows, coordinated action urgently needed to address root causes of irregular migration and keep children safe – Statement from UNICEF Executive Director Henrietta Fore
26/06/2019

Press release
Access to basic sanitation still lagging for millions in East and Southern Africa
UNICEF convenes sanitation stakeholders to strengthen regional and local markets for equitable access for children and their families
25/06/2019

Vaccine Confidence Project [to 29 Jun 2019]
http://www.vaccineconfidence.org/
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 29 Jun 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

Wellcome Trust [to 29 Jun 2019]
https://wellcome.ac.uk/news
Opinion | 27 June 2019
New programme to explore how innovation in health data can benefit everyone
James Thomas, Chief Technology Officer Wellcome
Artificial intelligence (AI) and data technologies are transforming research and healthcare. To ensure everyone can benefit from health data innovation, Wellcome is investing £75 million in a five-year programme on data for science and health

24 June 2019
Christiane Hertz-Fowler joining Wellcome to head our Infection and Immunobiology team

Funding Scheme: Impact of Vaccines on Antimicrobial Resistance
This scheme supports researchers investigating the impact of vaccines on antibiotic use and/or antimicrobial resistance. The aim is to support and inform vaccine decision-makers around the world and tackle antimicrobial resistance.
Scheme at a glance
:: Career stage: Leading a research program
:: Where your host organisation is based: Anywhere in the world
:: Level of funding: Small awards are up to £250,000. Large awards are £250,000 to £750,000.
:: Duration of funding: Flexible, depending on level of funding
:: Expressions of interest submitted by email
As soon as possible – no later than 6 September 2019, 17:00 BST
:: Invited full applications deadline
12 September 2019, 17:00 BST

The Wistar Institute [to 29 Jun 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.

World Organisation for Animal Health (OIE) [to 29 Jun 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

 

::::::

BIO [to 29 Jun 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 29 Jun 2019]
http://www.dcvmn.org/
No new digest content identified.

IFPMA [to 29 Jun 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.

PhRMA [to 29 Jun 2019]
http://www.phrma.org/press-room
No new digest content identified.

 

Industry Watch
:: CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26
June 26, 2019 04:45 PM Eastern Daylight Time
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to recommend HPV vaccination with GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) based on shared clinical decision making for individuals 27 through 45 years of age who are not adequately vaccinated. The ACIP also voted to expand routine and catch-up recommendations for males through 26 years of age who are not adequately vaccinated. The CDC currently recommends routine vaccination of females and males 11-12 years of age, and vaccination can begin at age 9. If approved by the CDC, GARDASIL 9 recommendations would be expanded to include females and males 13-26 years of age who have not previously been vaccinated, and for adults 27-45 years of age the decision to vaccinate would be made between an individual and their healthcare provider.

Details of the ACIP recommendations for GARDASIL 9 will be available from the CDC. The provisional recommendations are reviewed by the director of the CDC and the Department of Health and Human Services and final recommendations will become official when published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).

GARDASIL 9 is indicated for use in females aged 9-45 for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11. GARDASIL 9 is also indicated for use in males aged 9-45 for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11.

GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant].

In the U.S., almost half of new HPV infections occur in adults 25 years of age or older. Approximately 23,000 Americans are diagnosed with cervical, vaginal, vulvar, and anal cancers associated with HPV every year, according to latest published incidence from 2015. The nine types of HPV covered in GARDASIL 9 cause the majority of HPV-related cancers and other diseases in women and men. Even though adults may have already been exposed to some types of HPV covered by the vaccine, GARDASIL 9 may help protect against certain cancers and diseases caused by any of the nine HPV types to which someone has not yet been exposed.

“With more than a 100-year legacy in vaccines, Merck is deeply passionate about impacting public health through providing our broad portfolio of vaccines to people around the world,” said Dr. Richard M. Haupt, vice president and head of vaccines and infectious diseases, Global Medical Affairs at Merck. “We applaud the ACIP and the CDC for their continued efforts to address the significant burden of HPV-related cancers by continuously evaluating vaccination recommendations utilizing a comprehensive body of scientific evidence.”…